Neuromagen Pharma is a pharmaceutical company that is dedicated to developing a new class of drugs for neurodegenerative diseases. Their innovative small molecules activate Telomerase Reverse Transcriptase (TERT), a crucial enzyme that plays a significant role in preventing cellular senescence. Their goal is to delay the onset and progression of neurodegenerative diseases, especially ALS, in order to improve and extend patients' lives.

The scientific research conducted by Neuromagen Pharma has demonstrated the neuroprotective effects of TERT in the brain and spinal cord. They are currently developing a family of synthetic small molecules (AGS) that activate TERT transcription. These compounds have shown remarkable therapeutic results in various murine models of neurodegenerative diseases, including ALS and Alzheimer's disease.

The pipeline team at Neuromagen Pharma is led by experienced professionals who are dedicated to advancing their research and development efforts. Their senior clinical and regulatory advisor, Dr. Hananel Elul, has extensive experience in molecular biology methods and techniques.

The scientific advisory board includes renowned experts in neurology and molecular medicine. With their commitment to developing innovative treatments, Neuromagen Pharma is at the forefront of finding solutions for neurodegenerative diseases. Through their research and development efforts, they aim to make a significant impact on the lives of patients suffering from these devastating conditions